Tivozanib - FOTIVDA® (EMEA)
According to the NCI website tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities.
EMEA (EPAR was last updated on 28/11/2019)
- Fotivda is a medicine for treating adults with advanced renal cell carcinoma (a kidney cancer).
- Fotivda may be used in previously untreated patients or in those whose disease has got worse despite treatment with another medicine working in a different way.